Inside Health Policy wrote about the Trump administration launching the new TrumpRx platform as a portal to significant discounts on widely-prescribed drugs.
Similarly, the Council for Affordable Health Coverage says the recent HHS OIG advisory opinion could have a chilling effect on TrumpRx by not allowing the discounted costs to be used within a patient’s federal health plan coverage. CAHC welcomes the platform but says more action is needed to fix this issue and significantly increase the uptake of TrumpRx for more than 150 million Americans who get their prescription medicines through a federal health program.